Table 1. Baseline demographic and clinical profile.
| Baseline characteristics | Survivors (n = 49) | Non-survivors (n = 17) |
|---|---|---|
| Age (years) | 26 (19–31) | 32 (19–52) |
| Male gender (%) | 61% | 72% |
| Weight (kg) | 50 (45–58) | 52 (44–63) |
| Amount ingested (ml) | 20 (10–35) | 20 (20–250) |
| Time to admission from ingestion (hours) | 3.2 (1.7–7.0) | 4.2 (2.1–11.0) |
| Pulse (beats/minutes) | 80 (80–88) | 82 (77–90) |
| BP systolic (mm Hg) | 115 (110–120) | 115 (108–122) |
| BP diastolic (mm Hg) | 70 (70–80) | 80 (70–80) |
| Serum creatinine (mg/dl) | 0.7 (0.6–0.9) | 1.4 (1.2–1.5)* |
| Serum Cystatin C (mg/l) | 0.7 (0.6–0.8) | 0.8 (0.7–0.9) |
| eGFR (ml/min)£ | 102 (75–138) | 55 (48–66)* |
| eGFR (ml/min)$ | 112 (87–124) | 113 (103–123) |
| Time to AKIN1 (hours) | 19 (16–29) | 16 (9–24) |
| Time to AKIN2 (hours) | 24 (16–46) | 24 (16–48) |
| Time to AKIN3 (hours) | 40 (24–55) | 35 (14–48) |